Group One Trading’s Taysha Gene Therapies TSHA Stock Holding History

Group One Trading’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2K	Buy	+1,939	New	+$11.5K	﹤0.01%	6243
2026 Q1	–	Sell	-44,195	Closed	-$205K	–	8783
2025 Q4	$243K	Buy	44,195 +42,441	+2,420%	+$206K	﹤0.01%	4201
2025 Q3	$5.74K	Buy	+1,754	New	+$4.97K	﹤0.01%	7470
2024 Q1	–	Sell	-12,032	Closed	-$25.1K	–	7979
2023 Q4	$21.3K	Buy	12,032 +6,410	+114%	+$12.8K	﹤0.01%	5705
2023 Q3	$17.8K	Buy	+5,622	New	+$10.5K	﹤0.01%	5970
2023 Q2	–	Sell	-3,991	Closed	-$2.89K	–	8231
2023 Q1	$3.18K	Buy	3,991 +3,547	+799%	+$4.58K	﹤0.01%	6478
2022 Q4	$1K	Buy	+444	New	+$899	﹤0.01%	6830

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Group One Trading's TSHA Position: Q2 2026 in Review

Group One Trading opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 1,939 shares worth $13.2K. The stake represents ﹤0.01% of the portfolio and ranks #6243 among its holdings. This is a return to the name: Group One Trading previously reported a position in TSHA as recently as Q4 2025.

Group One Trading first reported a position in TSHA in Q4 2022 and has held it in 7 quarters since. The position peaked at $243K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Group One Trading held 1,939 shares of Taysha Gene Therapies worth $13.2K as of Q2 2026.
Taysha Gene Therapies was a new Group One Trading position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6243 holding.
Group One Trading first reported a position in Taysha Gene Therapies in Q4 2022 and has held it in 7 quarters since.
Group One Trading's Taysha Gene Therapies position peaked at $243K in Q4 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.